In relation to the question of different GLP-1 agonists, this was covered in a post previously on Hotcopper: Dr Sinclair responded via a tweet that was copied onto this forum. I can't find it unfortunately but she explained that exenatide has a unique effect on intracranial pressure that is not shared by other GLP-1 agonists like Semaglutide.
Great news as it provides another layer of protection for Invex on top of the orphan designation and the patent portfolio.
In relation to the question of different GLP-1 agonists, this...
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.012M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28219 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.6¢ | 2202 | 1 |
View Market Depth
| Last trade - 16.12pm 03/05/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable